EIB Global backs Vacsera vaccine facility in Egypt
- EIB Global signed a €750,000 technical assistance agreement to support preparation of a Vacsera vaccine facility in Egypt.
- The technical assistance will finance a feasibility study and market analysis for an estimated €50 million multi-product vaccine project.
- The investment aims to expand domestic and regional production, including exports to other African countries, and supports the AU target of 60% local vaccine production by 2040 (currently ~1%).
- The TA is financed under the FEMIP Trust Fund, aligns with the EU Global Gateway strategy, and could underpin potential future EIB financing once studies are completed.
Agreement and purpose
EIB Global signed a €750,000 technical assistance cooperation agreement to support preparation of Vacsera’s Vaccine Production Capacity Increase Project. The funds will support a feasibility study and market analysis to prepare a new multi-product vaccine facility.
Project scope and cost
The planned investment is estimated at approximately €50 million and aims to expand vaccine production capacity in Egypt, with part of production planned for export to other African countries.
Strategic context
The project aligns with the EU Global Gateway strategy and is financed under the FEMIP Trust Fund. It aims to strengthen health systems, promote equitable access to health products, and contribute to the African Union objective of increasing locally produced vaccines from about 1% today to 60% by 2040.
Signatories and next steps
The agreement was signed by H.E. Badr Abdelatty and EIB Vice-President Gelsomina Vigliotti, with Vacsera as a signatory. Vacsera is Egypt’s national vaccine manufacturer and one of Africa’s oldest vaccine producers. The studies financed by the TA are expected to underpin potential future EIB financing, the amount of which will be determined after completion of the studies.
Source: EIB